New hope for stubborn high blood pressure: experimental drug SAL0140 enters phase 2 trial
NCT ID NCT07654140
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests an experimental drug called SAL0140 in people whose high blood pressure remains high despite current treatments. About 252 adults aged 18-75 with uncontrolled hypertension will receive either the drug or a placebo for 12 weeks. The goal is to see if SAL0140 safely lowers blood pressure more than a placebo.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UNCONTROLLED HYPERTENSION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beijing Anzhen Hospital Capital Medical University
RECRUITINGBeijing, Beijing Municipality, 100029, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Zapping kidney nerves: a new hope for stubborn high blood pressure?
- New drug aims to tame stubborn high blood pressure
- New pill aims to tame stubborn high blood pressure
- Can your smartwatch really track blood pressure? new study puts wearables to the test
- Can a home BP monitor and a support team close the hypertension gap for black patients?
- Zapping kidney nerves may tame tough blood pressure